TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07441642: A Randomized, Double Masked, Placebo-controlled, Multicenter, Dose-range Finding Study to Assess the Efficacy and Safety of FWY003 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 272 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$5,079,600

Rescue Site Savings

+$3,353,200

Unlock Full NCT07441642 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07441642 Rescue Dossier →